Publications
Detailed Information
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cortes, Javier | - |
dc.contributor.author | Hurvitz, Sara A. | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Iwata, Hiroji | - |
dc.contributor.author | Curigliano, Giuseppe | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Chiu, Joanne W. Y. | - |
dc.contributor.author | Pedrini, Jose L. | - |
dc.contributor.author | Li, Wei | - |
dc.contributor.author | Yonemori, Kan | - |
dc.contributor.author | Bianchini, Giampaolo | - |
dc.contributor.author | Loi, Sherene | - |
dc.contributor.author | Borges, Giuliano S. | - |
dc.contributor.author | Wang, Xian | - |
dc.contributor.author | Bachelot, Thomas | - |
dc.contributor.author | Nakatani, Shunsuke | - |
dc.contributor.author | Ashfaque, Shahid | - |
dc.contributor.author | Liang, Zhengkang | - |
dc.contributor.author | Egorov, Anton | - |
dc.contributor.author | Hamilton, Erika | - |
dc.date.accessioned | 2024-09-12T04:53:09Z | - |
dc.date.available | 2024-09-12T04:53:09Z | - |
dc.date.created | 2024-09-11 | - |
dc.date.created | 2024-09-11 | - |
dc.date.created | 2024-09-11 | - |
dc.date.issued | 2024-08 | - |
dc.identifier.citation | Nature Medicine, Vol.30 No.8, pp.2208-2215 | - |
dc.identifier.issn | 1078-8956 | - |
dc.identifier.uri | https://hdl.handle.net/10371/209111 | - |
dc.description.abstract | Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and exploratory efficacy endpoints (median follow-up, 41 months) of DESTINY-Breast03. Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were randomized to T-DXd (5.4 mg per kg (261 patients)) or T-DM1 (3.6 mg per kg (263 patients)). The primary endpoint was progression-free survival (PFS) by blinded independent central review and was previously reported. The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, duration of response and PFS (all by investigator assessment) and safety. At data cutoff, 20 November 2023, median PFS by investigator assessment was 29.0 versus 7.2 months (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.24-0.38), the 36-month PFS rate was 45.7% versus 12.4% and median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56-0.94) with T-DXd versus T-DM1, respectively. Treatment-emergent adverse events were consistent with the previous analyses. No new instances of grade >= 3 interstitial lung disease or pneumonitis occurred (all grade rate, 16.7% (T-DXd) versus 3.4% (T-DM1)). With longer follow-up, T-DXd continued to demonstrate superior efficacy over T-DM1 with a manageable safety profile. ClinicalTrials.gov registration: NCT03529110. Secondary and selected exploratory endpoints of the DESTINY-Breast03 trial of trastuzumab deruxtecan or trastuzumab emtansine in patients with advanced HER2-positive breast cancer are reported, including updated efficacy and safety data after a median follow-up of 41 months. | - |
dc.language | 영어 | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1038/s41591-024-03021-7 | - |
dc.citation.journaltitle | Nature Medicine | - |
dc.identifier.wosid | 001236852700001 | - |
dc.identifier.scopusid | 2-s2.0-85194922060 | - |
dc.citation.endpage | 2215 | - |
dc.citation.number | 8 | - |
dc.citation.startpage | 2208 | - |
dc.citation.volume | 30 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE GUIDELINE | - |
dc.subject.keywordPlus | ANTIBODY-DRUG CONJUGATE | - |
dc.subject.keywordPlus | AMERICAN SOCIETY | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | DS-8201A | - |
dc.subject.keywordPlus | HER2 | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | PLUS | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.